Oncology – Page 8

Enhanced Survival in EGFR-Mutated NSCLC: The Impact of Combining Osimertinib with Chemotherapy

By MedXY 10/25/2025

This article reviews the latest evidence demonstrating improved overall survival with osimertinib combined with chemotherapy in first-line treatment of EGFR-mutated advanced non-small-cell lung cancer.

Dermatology Oncology

Nine-Year Outcomes of Nivolumab vs Ipilimumab in Resected Stage III/IV Melanoma: Sustained Survival Benefit and Safety

By MedXY 10/25/2025

The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.

news Oncology Urology

Enhancing Survival in Biochemically Recurrent Prostate Cancer: The Promising Role of Enzalutamide

By MedXY 10/25/2025

This review highlights the recent findings from the EMBARK trial demonstrating improved overall survival with enzalutamide combined with leuprolide in high-risk recurrent prostate cancer.

Oncology Otorhinolaryngology

Evaluating Atezolizumab Maintenance Therapy in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Insights from the IMvoke010 Trial

By MedXY 10/25/2025

Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting.

Oncology Pathology & Lab Medicine Urology

ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer: Translating Precision Oncology into Improved Outcomes

By MedXY 10/25/2025

This review synthesizes pivotal evidence from the IMvigor011 trial demonstrating that ctDNA-guided adjuvant atezolizumab significantly improves disease-free and overall survival in muscle-invasive bladder cancer, enabling risk-adapted immunotherapy after cystectomy.

news Oncology Urology

Long-Term Efficacy and Safety of Belzutifan in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma: Insights from the 50-Month LITESPARK-004 Phase 2 Study

By MedXY 10/25/2025

Belzutifan demonstrates sustained tumor response and manageable safety over 50 months in patients with von Hippel-Lindau disease-associated renal cell carcinoma, supporting its role as a systemic therapy.

Oncology Urology

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

By MedXY 10/25/2025

This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.

Diabetes & Endocrinology Oncology

Targeting Tumor Hypoxia Pathways: Belzutifan’s Promise in Advanced Paraganglioma and Pheochromocytoma Treatment

By MedXY 10/25/2025

This article reviews a phase 2 trial of belzutifan, a HIF-2α inhibitor, demonstrating durable antitumor activity and manageable safety in advanced pheochromocytoma and paraganglioma, highlighting its potential as a targeted therapy.

Oncology

Cutting-Edge Treatment for EGFR-Mutated NSCLC: Sacituzumab Tirumotecan Shows Promising Survival Benefits

By MedXY 10/25/2025

A phase 3 trial demonstrates that sacituzumab tirumotecan significantly improves progression-free and overall survival in EGFR-mutated advanced NSCLC resistant to TKI therapy.

OB/GYN & Women's Health Oncology

Advancing Treatment in Untreated Advanced Triple-Negative Breast Cancer: The Promising Role of Sacituzumab Govitecan

By MedXY 10/24/2025

This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.

Oncology Urology

Breakthrough ADC-Based Combination Therapy Achieves Over 95% Disease Control in Advanced Urothelial Cancer

By MedXY 10/24/2025

Datroway combined with rilvegostomig demonstrates impressive tumor response and disease control in advanced urothelial carcinoma, heralding a new therapeutic option in first- and second-line settings.

Allergy & Immunology Oncology

More Than Half of Patients Experience Tumor Shrinkage! Clinical Data Unveiled for a Potential “First-in-Class” Therapy

By MedXY 10/24/2025

Marengo Therapeutics reports promising Phase 2 results for invikafusp alfa, showing significant tumor shrinkage and disease control in advanced solid tumors with high mutation burden or MSI-H/dMMR.

OB/GYN & Women's Health Oncology

Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

By MedXY 10/24/2025

Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survival trends.

Oncology

Gedatolisib Demonstrates Promising Efficacy in Phase 3 VIKTORIA-1 Trial for HR+/HER2- Advanced Breast Cancer: NDA Submission Initiated

By MedXY 10/24/2025

Celcuity's phase 3 VIKTORIA-1 trial reveals that gedatolisib, a broad-spectrum PI3K/mTORC1/2 inhibitor, significantly improves progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer patients post CDK4/6 inhibitor therapy, prompting NDA rolling submission.

news Oncology

Promising Dual-Antibody Therapy Petosemtamab Shows Remarkable Response in Metastatic Colorectal Cancer

By MedXY 10/24/2025

Mid-phase clinical data reveal petosemtamab combined with FOLFOX/FOLFIRI achieves up to 100% response in first-line left-sided metastatic colorectal cancer, with manageable safety profile and potential to address unmet needs in mCRC treatment.

Dermatology General Surgery Oncology

Refining Sentinel Lymph Node Biopsy Decisions in Melanoma: Insights from the MERLIN_001 Gene Expression Profiling Study

By MedXY 10/24/2025

The MERLIN_001 study validates a combined clinicopathological and gene expression profile test that accurately predicts sentinel lymph node metastasis risk in patients with cutaneous melanoma, potentially guiding safer, more personalized surgical decisions.

Cardiology news Oncology

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

By MedXY 10/24/2025

A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.

AI Oncology Pathology & Lab Medicine

Harnessing Cancer-Testis Antigens for Precision Immunotherapy in Head and Neck Cancer

By MedXY 10/24/2025

This study identifies specific cancer-testis antigens (CTAs) as promising targets for personalized immunotherapy in head and neck squamous cell carcinoma (HNSCC), validated across multiomic datasets to enhance therapeutic precision.

Dentistry Oncology

Enhancing Masticatory Function After Mandibulectomy for Oral Cancer: Key Factors and Clinical Implications

By MedXY 10/24/2025

This review highlights the multifactorial determinants of masticatory function in patients rehabilitated after mandibulectomy, emphasizing the crucial role of posterior occlusal supports.

Dentistry Oncology Otorhinolaryngology Rehabilitation Medicine

Enhancing Oral Function through Long-Term Rehabilitation in Tongue and Non-Tongue Cancer Patients

By MedXY 10/24/2025

This review examines a study on the long-term impact of an oral rehabilitation program on patients with and without tongue cancer, highlighting benefits and clinical implications.